Skip to main content
Top
Published in: Clinical Rheumatology 2/2007

01-02-2007 | Original Article

Comparison of serum IL-1β, sIL-2R, IL-6, and TNF-α levels with disease activity parameters in ankylosing spondylitis

Authors: A. Bal, E. Unlu, G. Bahar, E. Aydog, E. Eksioglu, R. Yorgancioglu

Published in: Clinical Rheumatology | Issue 2/2007

Login to get access

Abstract

Ankylosing spondylitis (AS) is a chronic, inflammatory, rheumatological disease affecting primarily the sacroiliac joint and vertebral column, with an etiology that remains obscure. Cytokines are soluble proteins that have specific roles in inflammatory response, arranging the interaction between cells of the immune system both in natural and specific immune reactions. This study was planned to evaluate the relation between the level of cytokines and the clinical and laboratory findings of patients with AS compared to healthy subjects. In this study, we demonstrated increased serum levels of soluble interleukin-2 receptor (sIL-2R), Interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) in patients with AS compared with healthy subjects. Only IL-1β levels were not increased in AS patients. We found a correlation between C-reactive protein and IL-6 levels and between erythrocyte sedimentation rate and sIL-2R, IL-6 and TNF-α levels. Only the sIL-2R level was correlated with Bath AS Metrology Index and Bath AS Functional Index. We suggest that sIL-2R, IL-6, and TNF-α may have a role in the pathogenesis of AS and that their serum levels can be used as disease activity parameters and tools for diagnosis.
Literature
1.
go back to reference Banks RE, Whicher T, Thompson D, Bird HA (1998) Investigation of the rheumatic diseases. In: Maddison PJ, Isenberg DA, Woo P, Glass DN (eds) Oxford textbook of rheumatology. Oxford University Press, New York, pp 623–631 Banks RE, Whicher T, Thompson D, Bird HA (1998) Investigation of the rheumatic diseases. In: Maddison PJ, Isenberg DA, Woo P, Glass DN (eds) Oxford textbook of rheumatology. Oxford University Press, New York, pp 623–631
2.
go back to reference Dinarello CA, Moldawer LL (1999) Proinflammatory and anti-inflammatory cytokines in rheumatoid arthritis. Amgen, Thousand Oaks, CA Dinarello CA, Moldawer LL (1999) Proinflammatory and anti-inflammatory cytokines in rheumatoid arthritis. Amgen, Thousand Oaks, CA
3.
go back to reference Toussirot E, Lafforgue P, Boucraut J et al (1994) Serum levels of IL-1β, tumor necrosis factor-α, soluble interleukin 2 receptor and soluble CD8 in seronegative spondyloarthropathies. Rheumatol Int 13:175–180CrossRefPubMed Toussirot E, Lafforgue P, Boucraut J et al (1994) Serum levels of IL-1β, tumor necrosis factor-α, soluble interleukin 2 receptor and soluble CD8 in seronegative spondyloarthropathies. Rheumatol Int 13:175–180CrossRefPubMed
4.
go back to reference Keystone EC, Jaglal S, Shore A (1986) Interleukin 1 and interleukin 2 generation by peripheral blood cells from patients with ankylosing spondylitis. J Rheumatol 13(5):944–947PubMed Keystone EC, Jaglal S, Shore A (1986) Interleukin 1 and interleukin 2 generation by peripheral blood cells from patients with ankylosing spondylitis. J Rheumatol 13(5):944–947PubMed
5.
go back to reference Dinarello CA (1989) Interleukin-1 and other growth factors. In: Kelly WN et al (eds) Textbook of rheumatology, 3rd edn. Saunders, Philadelphia, PA, pp 285–299 Dinarello CA (1989) Interleukin-1 and other growth factors. In: Kelly WN et al (eds) Textbook of rheumatology, 3rd edn. Saunders, Philadelphia, PA, pp 285–299
6.
go back to reference Lipsky PE, Van der Heijde DM, St Clair EW et al (2003) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with Concomitant Therapy Study Group. N Engl J Med 343:1594–1602CrossRef Lipsky PE, Van der Heijde DM, St Clair EW et al (2003) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with Concomitant Therapy Study Group. N Engl J Med 343:1594–1602CrossRef
7.
go back to reference Moreland LW, Schiff MH, Baumgartner SW et al (1999) Etanercept theraphy in rheumatoid arthritis. A randomized controlled trial. Ann Intern Med 130:478–486PubMed Moreland LW, Schiff MH, Baumgartner SW et al (1999) Etanercept theraphy in rheumatoid arthritis. A randomized controlled trial. Ann Intern Med 130:478–486PubMed
8.
go back to reference Rudwaleit M, Listing J, Brandt J et al (2004) Prediction of a major clinical response (BASDAI 50) to tumor necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 63(6):665–670CrossRefPubMed Rudwaleit M, Listing J, Brandt J et al (2004) Prediction of a major clinical response (BASDAI 50) to tumor necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 63(6):665–670CrossRefPubMed
9.
go back to reference Keller C, Webb A, Davis J (2003) Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review. Ann Rheum Dis 62(12):1128–1132CrossRefPubMed Keller C, Webb A, Davis J (2003) Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review. Ann Rheum Dis 62(12):1128–1132CrossRefPubMed
10.
go back to reference Goei A, Steven MM, Sjef M et al (1985) Evaluation of diagnostic criteria for ankylosing spondylitis. A comparison of the Rome, New York and modified New York criteria in patients with a positive clinical history screening test for ankylosing spondylitis. Br J Rheumatol 24:242–249PubMed Goei A, Steven MM, Sjef M et al (1985) Evaluation of diagnostic criteria for ankylosing spondylitis. A comparison of the Rome, New York and modified New York criteria in patients with a positive clinical history screening test for ankylosing spondylitis. Br J Rheumatol 24:242–249PubMed
11.
go back to reference Garret S, Jenkinson T et al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291PubMed Garret S, Jenkinson T et al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291PubMed
12.
go back to reference Cain A, Garret S et al (1994) A new approach to defining functional ability in ankylosing spondylitis. The development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285PubMed Cain A, Garret S et al (1994) A new approach to defining functional ability in ankylosing spondylitis. The development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285PubMed
13.
go back to reference Kennedy LG et al (1993) Ankylosing spondylitis: the correlation between a new metrology score and radiology. Br J Rheumatol 34:767–770 Kennedy LG et al (1993) Ankylosing spondylitis: the correlation between a new metrology score and radiology. Br J Rheumatol 34:767–770
14.
go back to reference Vazquez-Del Mercado M et al (2002) Interleukin 1β (IL-1β), IL-10, tumor necrosis factor-α and cellular proliferation index in peripheral blood mononuclear cells in patient with ankylosing spondylitis. J Rheumatol 29(3):522–526PubMed Vazquez-Del Mercado M et al (2002) Interleukin 1β (IL-1β), IL-10, tumor necrosis factor-α and cellular proliferation index in peripheral blood mononuclear cells in patient with ankylosing spondylitis. J Rheumatol 29(3):522–526PubMed
15.
go back to reference Mc Cormack PL, Wellington K (2004) Etanercept: in ankylosing spondylitis. BioDrugs 18(3):199–205 (discussion 206)CrossRefPubMed Mc Cormack PL, Wellington K (2004) Etanercept: in ankylosing spondylitis. BioDrugs 18(3):199–205 (discussion 206)CrossRefPubMed
16.
go back to reference Haibel H, Rudwaleit M, Listing J et al (2005) Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 64(2):296–298CrossRefPubMed Haibel H, Rudwaleit M, Listing J et al (2005) Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 64(2):296–298CrossRefPubMed
17.
go back to reference Gratacos J et al (1994) Serum cytokines (IL-6, TNF-α, IL-1β and IFN-δ) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 33:927–931 Gratacos J et al (1994) Serum cytokines (IL-6, TNF-α, IL-1β and IFN-δ) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 33:927–931
18.
go back to reference Sonel B, Tutkak H, Duzgun N (2002) Serum levels of IL-1beta, TNF-alfa, IL-8 and acute phase proteins in seronegative spondyloarthropathies. Joint Bone Spine 69:463–467CrossRefPubMed Sonel B, Tutkak H, Duzgun N (2002) Serum levels of IL-1beta, TNF-alfa, IL-8 and acute phase proteins in seronegative spondyloarthropathies. Joint Bone Spine 69:463–467CrossRefPubMed
19.
go back to reference Liu HC, Hsieh KH (1987) Elevated serum interleukin-2 receptor; increased in vitro immunoglobulin synthesis and lack of response to testosterone-enhanced in vitro interleukin-2 production in ankylosing spondylitis. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi 20(1):1–8PubMed Liu HC, Hsieh KH (1987) Elevated serum interleukin-2 receptor; increased in vitro immunoglobulin synthesis and lack of response to testosterone-enhanced in vitro interleukin-2 production in ankylosing spondylitis. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi 20(1):1–8PubMed
20.
go back to reference Tutuncu ZN et al (1994) Interleukin-6 acute phases reactance and clinical status in ankylosing spondylitis. Ann Rheum Dis 53:425–428PubMedCrossRef Tutuncu ZN et al (1994) Interleukin-6 acute phases reactance and clinical status in ankylosing spondylitis. Ann Rheum Dis 53:425–428PubMedCrossRef
21.
go back to reference Claudepierre P, Rymer J-C, Authier F-J et al (1997) A relationship between TGF-β1 or IL-6 plasma levels and clinical features of spondyloarthropathies. Br J Rheumatol 37:400–406CrossRef Claudepierre P, Rymer J-C, Authier F-J et al (1997) A relationship between TGF-β1 or IL-6 plasma levels and clinical features of spondyloarthropathies. Br J Rheumatol 37:400–406CrossRef
22.
go back to reference Falkenbach A, Herold M (1998) In ankylosing spondylitis serum interleukin-6 correlates with the degree of mobility restriction, but not with short-term changes in the variables for mobility. Rheumatol Int 18:103–106CrossRefPubMed Falkenbach A, Herold M (1998) In ankylosing spondylitis serum interleukin-6 correlates with the degree of mobility restriction, but not with short-term changes in the variables for mobility. Rheumatol Int 18:103–106CrossRefPubMed
23.
go back to reference Taylor PC, Williams RO, Feldman M (2004) Tumour necrosis factor α as a therapeutic target for immune-mediated inflammatory diseases. Curr Opin Biotechnol 15:557–563CrossRefPubMed Taylor PC, Williams RO, Feldman M (2004) Tumour necrosis factor α as a therapeutic target for immune-mediated inflammatory diseases. Curr Opin Biotechnol 15:557–563CrossRefPubMed
Metadata
Title
Comparison of serum IL-1β, sIL-2R, IL-6, and TNF-α levels with disease activity parameters in ankylosing spondylitis
Authors
A. Bal
E. Unlu
G. Bahar
E. Aydog
E. Eksioglu
R. Yorgancioglu
Publication date
01-02-2007
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 2/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-006-0283-5

Other articles of this Issue 2/2007

Clinical Rheumatology 2/2007 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.